文献速递前列腺癌

转移性激素敏感性前列腺癌的系统治疗:网络荟萃分析

Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis.
PubMed 文献 · BJU Int · 2021-07-21

该网络荟萃分析纳入9项研究共9960例mHSPC患者,比较现有系统治疗的疗效与安全性。阿比特龙、多西他赛和恩扎卢胺均显著改善OS,阿比特龙最佳;恩扎卢胺在PFS上最佳;三种ARIs均较多西他赛更有效,阿帕鲁胺耐受性最佳。

要点

  • 阿比特龙、多西他赛、恩扎卢胺均显著改善mHSPC患者OS,阿比特龙最佳。
  • 恩扎卢胺PFS最佳,三种ARIs均较多西他赛更有效。
  • 低瘤负荷mHSPC患者中,恩扎卢胺OS和PFS最佳。

核心结论

  • 三种ARIs均为mHSPC有效治疗,阿帕鲁胺耐受性最佳,且均较多西他赛更有效。

研究设计与样本

  • 系统综述与网络荟萃分析,检索截至2020年5月,纳入9项研究共9960例mHSPC患者。

主要发现

  • 阿比特龙(HR 0.83,95%CrI 0.76-0.90)、多西他赛(HR 0.90,95%CrI 0.82-0.98)、恩扎卢胺(HR 0.85,95%CrI 0.73-0.99)较ADT显著改善OS,阿比特龙最佳。
  • 阿比特龙(HR 0.71,95%CrI 0.67-0.76)、阿帕鲁胺(HR 0.73,95%CrI 0.65-0.81)、多西他赛(HR 0.84,95%CrI 0.78-0.90)、恩扎卢胺(HR 0.67,95%CrI 0.63-0.71)较ADT显著改善PFS,恩扎卢胺最佳。
  • 阿比特龙(HR 0.85,95%CrI 0.78-0.93)、阿帕鲁胺(HR 0.87,95%CrI 0.77-0.98)、恩扎卢胺(HR 0.80,95%CrI 0.73-0.88)较多西他赛显著更有效。
  • 不良事件方面,阿帕鲁胺可能是三种ARIs中最佳选择。
  • 低瘤负荷mHSPC患者中,恩扎卢胺OS和PFS最佳。

临床怎么用

  • 三种ARIs均可作为mHSPC治疗选择,阿帕鲁胺耐受性最佳。
  • 低瘤负荷患者可优先考虑恩扎卢胺。
  • 三种ARIs均较多西他赛更有效,支持个体化治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To perform a systematic review and network meta-analysis to compare the efficacy and safety of currently available treatments for the management of metastatic hormone-sensitive prostate cancer (mHSPC), as there has been a paradigm shift with the use of next-generation androgen receptor inhibitors (ARIs) and docetaxel. METHODS: Multiple databases were searched for articles published before May 2020 according to the Preferred Reporting Items for Systematic Review and Meta-analysis extension statement for network meta-analysis. Studies comparing overall/progression-free survival (OS/PFS) and/or adverse events (AEs) in patients with mHSPC were eligible. RESULTS: Nine studies (N = 9960) were selected, and formal network meta-analyses were conducted. Abiraterone (hazard ratio [HR] 0.83, 95% credible interval [CrI] 0.76-0.90), docetaxel (HR 0.90, 95% CrI 0.82-0.98), and enzalutamide (HR 0.85, 95% CrI 0.73-0.99) were associated with significantly better OS than androgen-deprivation therapy (ADT), and abiraterone emerged as the best option. Abiraterone (HR 0.71, 95% CrI 0.67-0.76), apalutamide (HR 0.73, 95% CrI 0.65-0.81), docetaxel (HR 0.84, 95% CrI 0.78-0.90), and enzalutamide (HR 0.67, 95% CrI 0.63-0.71) were associated with significantly better PFS than ADT, and enzalutamide emerged as the best option. Abiraterone (HR 0.85, 95% CrI 0.78-0.93), apalutamide (HR 0.87, 95% CrI 0.77-0.98), and enzalutamide (HR 0.80, 95% CrI 0.73-0.88) were significantly more effective than docetaxel. Regarding AEs, apalutamide was the likely best option among the three ARIs. In patients with low-volume mHSPC, enzalutamide was the best option in terms of OS and PFS. CONCLUSIONS: All three ARIs are effective therapies for mHSPC; apalutamide was the best tolerated. All three seemed more effective than docetaxel. These findings may facilitate individualised treatment strategies and inform future comparative trials.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Mori K, Mostafaei H, Sari Motlagh R, et al. Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. BJU Int. 2021. PMID: 34171173. doi:10.1111/bju.15507

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。